Search

Your search keyword '"Darr, Christopher"' showing total 244 results

Search Constraints

Start Over You searched for: Author "Darr, Christopher" Remove constraint Author: "Darr, Christopher"
244 results on '"Darr, Christopher"'

Search Results

1. Banking on the Future: Student Academic Performance, Retention, Graduation, and Instructor Type

3. Which Patients with Prostate Cancer and Lymph Node Uptake at Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography Scan Are at a Higher Risk of Prostate-specific Antigen Persistence After Radical Prostatectomy? Identifying Indicators of Systemic Disease by Integrating Clinical, Magnetic Resonance Imaging, and Functional Imaging Parameters

5. Identification of the Optimal Candidates for Nodal Staging with Extended Pelvic Lymph Node Dissection Among Prostate Cancer Patients Who Underwent Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography. External Validation of the Memorial Sloan Kettering Cancer Center and Briganti Nomograms and Development of a Novel Tool

6. Risk and predictors of adverse pathology after radical prostatectomy in patients diagnosed with IUSP 1–2 prostate cancer at MRI-targeted biopsy: a multicenter analysis

8. Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort

10. Detection of Clinically Significant Prostate Cancer Using Targeted Biopsy with Four Cores Versus Target Saturation Biopsy with Nine Cores in Transperineal Prostate Fusion Biopsy: A Prospective Randomized Trial

11. Subgroup analysis of real-world efficacy of enfortumab vedotin in patients with metastatic/locally advanced urothelial carcinoma from a European database.

12. Establishing medical intelligence - leveraging FHIR to improve clinical management

13. Variation across operating sites in urinary and sexual outcomes after radical prostatectomy in localized and locally advanced prostate cancer

14. Cabozantinib Plus Nivolumab in Adult Patients with Advanced or Metastatic Renal Cell Carcinoma: A Retrospective, Non-Interventional Study in a Real-World Cohort/GUARDIANS Project.

15. Impact of COVID-19 crisis on medical care of patients with metastasized uro-oncologic disease under systemic cancer therapy: a multicenter study in German university hospitals

17. PD17-07 CAN WE RELY ON AVAILABLE MODELS PREDICTING PATHOLOGICAL OUTCOMES IN PROSTATE CANCER PATIENTS STAGED WITH 68GA PSMA-PET/CT? EXTERNAL VALIDATION OF THE EXISTING NOMOGRAMS FOR EXTRACAPSULAR EXTENSION AND SEMINAL VESICLE INVASION AND DEVELOPMENT OF A NOVEL TOOL INCLUDING INTRAPROSTATIC SUVMAX

18. PD61-03 EXTERNAL VALIDATION OF THE AVAILABLE NOMOGRAMS FOR THE IDENTIFICATION OF CANDIDATES FOR a STAGING EXTENDED PELVIC LYMPH NODE DISSECTION AT THE TIME OF RADICAL PROSTATECTOMY IN PROSTATE CANCER PATIENTS PREOPERATIVELY STAGED WITH PSMA PET

19. MP14-01 RATES AND PREDICTORS OF FALSE NODE-POSITIVE PSMA-PET IN PATIENTS TREATED WITH RADICAL PROSTATECTOMY AND EXTEND PELVIC LYMPH-NODE DISSECTION: RESULTS FROM A LARGE, MULTI-INSTITUTIONAL DATABASE

20. MP31-19 “THE MORE YOU SEE THE MORE YOU MISS” PSMA PET/CT IS STILL AFFECTED BY A SUBSTANTIAL RISK OF UNDERESTIMATION IN PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY

21. MP14-18 ONCOLOGICAL OUTCOMES OF PN1 PROSTATE CANCER PATIENTS TREATED WITH RADICAL PROSTATECTOMY: DOES MOLECULAR IMAGING HAVE A PROGNOSTIC IMPACT? RESULTS OF A LARGE, MULTI-INSTITUTIONAL SERIES

22. NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer

25. Which Patients with Prostate Cancer and Lymph Node Uptake at Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography Scan Are at a Higher Risk of Prostate-specific Antigen Persistence After Radical Prostatectomy?: Identifying Indicators of Systemic Disease by Integrating Clinical, Magnetic Resonance Imaging, and Functional Imaging Parameters

26. Near‐infrared fluorescence lymph node template region dissection plus backup lymphadenectomy in open radical cystectomy for bladder cancer using an innovative handheld device: A single center experience.

31. Intraoperative Molecular Positron Emission Tomography Imaging for Intraoperative Assessment of Radical Prostatectomy Specimens

32. Clinical development of the bispecific PSMAxCD3 antibody CC-1.

33. A multicenter paper-based and web-based system for collecting patient-reported outcome measures in patients undergoing local treatment for prostate cancer: first experiences

35. Occurrence of NECTIN4 amplification in solid tumors and enfortumab vedotin response in metastatic urothelial cancer.

36. Safety and efficacy of enfortumab vedotin in patients with metastatic/locally advanced urothelial cancer: Real-world evidence from a European database.

39. Real world evidence from a retrospective multi-center analysis on first-line therapy for metastatic renal cell carcinoma with non-clear cell and/or sarcomatoid histologies.

40. Treatment options and outcome of patients with metastatic renal cell carcinoma with brain or bone metastases: Real world evidence from a German retrospective multi-center analysis.

41. Prediction models of incontinence and sexual function one year after radical prostatectomy based on data from 20 164 prostate cancer patients.

42. Debating Diversity: Ethics and Controversial Public Issues

44. Supplementary Data TS1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance

45. Data from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance

46. Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance

47. MP61-12 WHICH MEN WITH CN1 PROSTATE CANCER AT PSMA PET/CT REPRESENT THE IDEAL CANDIDATE TO RADICAL PROSTATECTOMY? DEVELOPMENT OF A NOVEL RISK STRATIFICATION TOOL FOR INDIVIDUALIZED APPROACHES BASED ON A LARGE, MULTI-INSTITUTIONAL SERIES

48. PD10-07 CAN WE RELY ON AVAILABLE MODELS TO IDENTIFY CANDIDATES FOR EXTENDED PELVIC LYMPH NODE DISSECTION (EPLND) IN MEN STAGED WITH PSMA-PET? EXTERNAL VALIDATION OF THE BRIGANTI NOMOGRAMS AND DEVELOPMENT OF A NOVEL TOOL TO IDENTIFY OPTIMAL CANDIDATES FOR EPLND

50. Cabozantinib + nivolumab in adult patients with advanced or metastatic renal cell carcinoma: A retrospective, non-interventional study in a real-world cohort.

Catalog

Books, media, physical & digital resources